Voloshin et al. hypothesized that the combined treatment of TTFields, with anti-PD-1 therapy led to an increase in PD-L1 density in tumor-infiltrating leukocytes of LLC-1 tumors, likely due to the elevated production of IFN-γ in CD8 + cells within the tumor environment15. Here, PDCD1 is linked to neoplasm.